[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526953":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oxytocin","EXPERIMENTAL","Participants receive 40 units IV oxytocin in 1000 mL of normal saline at the time of tenaculum placement for D\\&E.",[13],"Drug: Oxytocin + normal saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants receive 1000 mL of normal saline alone at the time of tenaculum placement for D\\&E.",[19],"Drug: Normal saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oxytocin + normal saline","40 units IV oxytocin once in a 1000 mL bag of normal saline",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal saline","1000 mL bag of normal saline alone",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Megan Masten, MD","CONTACT","303-724-8576","megan.masten@cuanschutz.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Comprehensive Women's Health Center","RECRUITING","Denver","Colorado","80230","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-104.9847,39.73915,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100526953","phase-2-changes-in-hemorrhage-with-prophylactic-oxytocin-for-dilation-and-evacuation-100526953",false,"NCT06141447","Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation","Changes in Rate of Hemorrhage With Prophylactic Oxytocin for Second Trimester Dilation and Evacuation in the Clinic Setting","Inclusion Criteria:\n\n* clinic-based D\\&E at 18 weeks gestational age and above\n* speaks English or Spanish\n\nExclusion Criteria:\n\n* refuses IV\n* history of coagulopathy\n* anticoagulant use in the preceding five days\n* chorioamnionitis or sepsis\n* suspected placenta accreta spectrum\n* intrauterine fetal demise\n* multiple gestation\n* use of misoprostol for cervical preparation",true,"FEMALE","18 Years","55 Years",{"count":68,"type":69},150,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D\\&E) in the clinic setting.",[75],"Hemorrhage","2024-12-05",{"date":78,"type":79},"2024-12-10","ACTUAL",{"date":81,"type":79},"2024-05-02",{"date":83,"type":69},"2026-11-02",{"name":5,"class":6},1]